Danaher Closes $9.9 Billion Masimo Acquisition, Deepening Patient Monitoring Capabilities
Danaher has completed its $9.9 billion acquisition of Masimo Corporation, integrating the patient monitoring and signal processing technology company into its diagnostics and life sciences portfolio in one of the largest acquisitions in Danaher's recent history.
Acquisition Complete
Danaher has closed its acquisition of Masimo Corporation for approximately $9.9 billion, adding the patient monitoring technology company to its growing diagnostics and life sciences portfolio. The deal brings Masimo's core measurement-in-motion and signal processing capabilities, most notably its SET pulse oximetry technology and Masimo SafetyNet patient monitoring platform, into Danaher's ecosystem alongside existing diagnostics brands.
Masimo holds a strong position in hospital patient monitoring: its pulse oximetry systems are used in intensive care, surgical, and emergency settings, and the company has been expanding into consumer health monitoring. The acquisition gives Danaher exposure to the hospital technology infrastructure market, complementing its existing laboratory, diagnostics, and bioprocessing businesses.
Strategic Logic and Integration Risk
Danaher has a well-established acquisition playbook, the Danaher Business System, which applies lean operating principles to acquired businesses to improve margins and efficiency over time. Masimo's technology base is complex and its patient monitoring business operates in a competitive market alongside Philips, GE HealthCare, and Medtronic, which adds integration complexity beyond typical life sciences bolt-ons.
Wolfe Research downgraded Danaher following the deal's close, flagging concerns that recovery in the bioprocessing end market may be slower than expected and that the Masimo integration will require sustained management attention. HSBC also cut its price target. Separately, Danaher insiders sold approximately $235 million worth of shares around the completion of the deal, a level of insider selling that some analysts have noted as a cautionary signal.
Bioprocessing Recovery
Beyond Masimo, Danaher's core bioprocessing segment, which supplies equipment and consumables for biopharmaceutical manufacturing, has been recovering after a post-pandemic destocking cycle. The Summit on Bioprocessing noted strong early signs of normalisation, and the segment's performance will be a key determinant of whether DHR's earnings recovery meets investor expectations in the second half of 2026.
Sources
Frequently asked questions
What does Masimo make?
Masimo is best known for its SET pulse oximetry technology and Masimo SafetyNet remote patient monitoring platform. Its devices are widely used in hospital ICUs, operating rooms, and emergency care settings.
What is the Danaher Business System?
The Danaher Business System is the company's proprietary lean operating methodology, applied to every acquisition to improve efficiency, quality, and margins. It is considered a key driver of Danaher's long-term value creation track record.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
One story is a data point. The pattern is the edge.
Reading one story at a time, you miss how the news adds up. Track DHR free and TradeTidings rolls every future headline into one clear positive, neutral or negative read, and alerts you the moment it turns.